JAMA Network
About The Study: This economic evaluation estimates that expanded Medicare coverage for glucagon-like peptide-1 receptor agonists (GLP-1RAs) would increase access and reduce obesity-related comorbidities but impose substantial costs over 10 years. Even with a moderate scenario (5% uptake, 20% adherence, and 30% additional price discount), net spending was still projected to reach $8 billion over a decade, underscoring the need for further price reductions, lower-cost strategies to prevent weight regain, and reductions in spending on low-value care.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
